News | April 18, 2013

Galectin-3 Test May Help Identify Patients at Highest Risk for a Worse Prognosis in Heart Failure

Test may quantify risk of re-hospitalization and death, allowing physicians to tailor the level of care to individual patient needs

April 18, 2013 — Abbott has received Conformite Europeene (CE) marking for the Architect Galectin-3 assay, a blood test to aid doctors in assessing the prognosis of patients diagnosed with chronic heart failure.

"Galectin-3 reflects the pathophysiology of heart failure and is one of the most powerful prognostic indicators in heart failure. It helps clinicians identify which patients are at high risk for worsening heart failure early in the course of their disease," said Dr. Rudolf de Boer, associate professor in cardiology at the University Medical Centre Groningen, the Netherlands. "Knowing which patients are at increased risk of hospital re-admission — independent of other variables — could provide physicians with important information to help them reach different decisions about treatment, which may benefit patient care."

Heart failure, or the inability of the heart to circulate blood effectively, is associated with poor patient outcomes, a lower quality of life, and recurrent and costly health services.  While the progress of heart failure is different for each patient, several studies demonstrate that heart failure patients with higher levels of a protein called galectin-3 present are more likely to have worse outcomes, including re-hospitalization and death.

"Despite numerous medical advances, the number of deaths among hospitalized heart failure patients remains high, exceeding that of most cancers," said Brian Blaser, executive vice president, Diagnostics Products, Abbott. "The new Architect Galectin-3 test is a helpful tool to aid physicians in their care of these critically ill patients."

The Architect Galectin-3 test is available in several European countries.

For more information:,

Related Content

Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing | April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing | April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing | April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing | March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing | January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing | July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
News | Blood Testing | March 22, 2016
March 22, 2016 — Critical Diagnostics announced that it entered into a license agreement for the exclusive worldwide
Overlay Init